Base de dados : LILACS
Pesquisa : D08.811.277.656.350.350.687 [Categoria DeCS]
Referências encontradas : 197 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 20 ir para página                         

  1 / 197 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1122676
Autor: García-Saavedra, Mario B; Rosales-Gutiérrez, Renzo R; Valverde, Esmeralda; Chumbes-Aguirre, Maryuri; Alvarado, Ricardo; Polo, Robert; Azañero, Rubén; Chávez, Carlos.
Título: Implicaciones cardiovasculares de la infección por SARS-CoV-2: revisión de literatura / Cardiovascular implications of SARS-CoV-2 infection: a literature review
Fonte: Medwave;20(7):e8008, 2020.
Idioma: en; es.
Resumo: En diciembre de 2019 se reportó en Wuhan, China, la aparición de una nueva cepa de coronavirus SARS-CoV-2 que producía un compromiso pulmonar severo y progresaba a estrés respiratorio agudo. A la fecha, son más de diecisiete millones los casos confirmados y más de medio millón los fallecidos en todo el mundo a causa de COVID-19. Los estudios reportan que los pacientes con enfermedad cardiovascular son más susceptibles a contraer esta enfermedad y a presentar más complicaciones. El propósito de esta revisión es proporcionar información actualizada para los profesionales de la salud que atienden a pacientes con COVID-19 y que tienen además enfermedad cardiovascular y por ende un riesgo elevado de complicaciones y mortalidad. Realizamos una búsqueda de bibliografía científica acerca de la asociación de enfermedad cardiovascular y COVID-19 en diferentes bases de datos como Scopus, MEDLINE vía PubMed y Cochrane Library. El tratamiento con inhibidores de la enzima convertidora de angiotensina y bloqueadores del receptor de angiotensina ha sido motivo de discusión y no hay evidencia sólida para contraindicarlo en pacientes con COVID-19. Respecto al tratamiento con hidroxicloroquina asociado o no con azitromicina, hay evidencia que demuestra un mayor riesgo con su utilización, que beneficio clínico y/o disminución de mortalidad. En este contexto, los pacientes con insuficiencia cardíaca representan un grupo importante de riesgo por su condición per se y por el dilema diagnóstico generado al evaluar un paciente con COVID-19, en el que los signos de insuficiencia cardíaca aguda podrían enmascararse. Por otro lado, en los pacientes con síndrome coronario agudo, el enfoque terapéutico inicial podría cambiar en el contexto de la pandemia, aunque sólo sobre la base de opiniones de expertos. Quedan, sin embargo, muchos temas en controversia que serán motivo de investigaciones futuras.

In December 2019, a new strain of the SARS-CoV-2 coronavirus was reported in Wuhan, China, which produced severe lung involvement and progressed to respiratory distress. To date, more than seventeen million confirmed cases and more than half a million died worldwide from COVID-19. Patients with cardiovascular disease are more susceptible to contracting this disease and presenting more complications. We did a literature search on the association of cardiovascular disease and COVID-19 in databases such as Scopus, PubMed/MEDLINE, and the Cochrane Library. The purpose of this review is to provide updated information for health professionals who care for patients with COVID-19 and cardiovascular disease, given that they have a high risk of complications and mortality. Treatment with angiotensin-converting enzyme inhibitors and receptor blockers is controversial, and there is no evidence not to use these medications in patients with COVID-19. Regarding treatment with hydroxychloroquine associated or not with azithromycin, there is evidence of a higher risk with its use than clinical benefit and decreased mortality. Likewise, patients with heart failure are an important risk group due to their condition per se. Patients with heart failure and COVID-19 are a diagnostic dilemma because the signs of acute heart failure could be masked. On the other hand, in patients with acute coronary syndrome, the initial therapeutic approach could change in the context of the pandemic, although only based on expert opinions. Nonetheless, many controversial issues will be the subject of future research.
Descritores: Doenças Cardiovasculares/complicações
SARS-CoV-2
COVID-19/complicações
-Antivirais/efeitos adversos
Prognóstico
Sistema Renina-Angiotensina/fisiologia
Algoritmos
Inibidores da Enzima Conversora de Angiotensina/uso terapêutico
Azitromicina/efeitos adversos
Peptidil Dipeptidase A/metabolismo
Quimioterapia Combinada
Eletrocardiografia/efeitos dos fármacos
Síndrome Coronariana Aguda/etiologia
Síndrome Coronariana Aguda/terapia
Pandemias
COVID-19/tratamento farmacológico
Insuficiência Cardíaca/etiologia
Insuficiência Cardíaca/terapia
Hidroxicloroquina/efeitos adversos
Hipertensão/complicações
Hipertensão/tratamento farmacológico
Limites: Humanos
Tipo de Publ: Revisão
Responsável: CL1.1 - Biblioteca Central


  2 / 197 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1254949
Autor: Ortíz López, Luis Angel; Morales León, Luis Alberto; Palazuelos Ramírez, David Fernando; Lam Rascón, José Francisco; Castillo Díaz, Luis Alberto.
Título: Papel de los tejidos orales durante la infección por SARS-CoV-2 / Role of oral tissues in SARS-CoV-2 infection
Fonte: Rev. ADM = ADM;78(3):167-175, mayo-jun. 2021. ilus.
Idioma: es.
Resumo: La actual pandemia de COVID-19 provocada por el virus SARS-CoV-2 es un problema de salud que afecta a la población globalmente. Su desarrollo puede ser asintomático o exhibir manifestaciones clínicas moderadas o severas dependiendo en gran medida de la respuesta inmune de quien la padece. Esta enfermedad afecta principalmente a los pulmones a través del desarrollo del síndrome respiratorio agudo severo (SRAS), tanto como por la «tormenta de citocinas¼, una respuesta inflamatoria exacerbada que podría provocar una falla multisistémica y, en casos severos, la muerte. Se conoce que la enzima convertidora de angiotensina 2 (ECA-2), presente en diversos tejidos del cuerpo, actúa como receptor funcional del virus SARS-CoV-2 facilitando la entrada de éste a las células. Se ha demostrado la presencia de dicho receptor en varios tejidos orales, por lo que se puede considerar a la cavidad bucal como una vía latente de infección por dicho coronavirus, ya que su mecanismo de transmisión es a través de la inhalación de partículas virales, ya sea por vía nasal u oral. Así mismo, la presencia de carga vírica en la saliva y algunos de los síntomas de la COVID-19, por ejemplo la ageusia, pueden indicar la presencia de contagio viral en etapas tempranas. La presente revisión muestra evidencia que sugiere que diversos tejidos en la cavidad oral podrían ser considerados sitios potenciales de contagio por el SARS-CoV-2, teniendo un papel importante en el mecanismo de transmisión y en el desarrollo de coinfecciones (AU)

The COVID-19 pandemic caused by the SARS-CoV-2 virus is currently a global healthcare problem. The onset of this disease can exhibit several clinical manifestations ranging from mild to severe symptoms, depending on the individual's immune response. COVID-19 primarily affects the lungs by developing the Severe Acute Respiratory Syndrome (SARS) and the «cytokine storm¼, an exacerbated inflammatory reaction that can lead to multiorgan failure and consequently death. The angiotensin-converting enzyme 2 (ACE-2), present in several tissues in the human body, is known to act as the functional receptor of the SARS-CoV-2 germ facilitating its entrance into the cells. Such receptor is also present in diverse oral cavity tissues, indicating a latent route of infection due to its influence in the transmission mechanism by inhalation, either oral or nasal, of virus particles. Also, viral load in saliva and taste disorder symptoms like ageusia could indicate a viral infection in its early stages. This article presents evidence suggesting that several tissues in the oral cavity can be considered potential sites of SARS-CoV-2 infection, thus playing an essential role in the transmission mechanism and development of co-infections (AU)
Descritores: SARS-CoV-2
COVID-19
Mucosa Bucal/patologia
-Manifestações Bucais
Sinais e Sintomas
Distúrbios do Paladar
Peptidil Dipeptidase A
Carga Viral
Inflamação
Limites: Humanos
Tipo de Publ: Revisão
Responsável: AR29.1 - Biblioteca


  3 / 197 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1126169
Autor: Cano, F; Gajardo, M; Freundlich, M.
Título: Eje Renina Angiotensina, Enzima Convertidora de Angiotensina 2 y Coronavirus / Renin Angiotensin Axis, Angiotensin Converting Enzyme 2 and Coronavirus
Fonte: Rev. chil. pediatr;91(3):330-338, jun. 2020. graf.
Idioma: es.
Resumo: Resumen: El sistema renina angiotensina aldosterona (SRAA) es el principal regulador del volumen plasmático, manteniendo la homeostasis cardiovascular e hidrosalina. En la vía clásica, la enzima convertidora de angiotensina (ECA) genera Angiotensina II (AngII), de potente efecto inflamatorio y vasoconstrictor. Esta vía clásica es a su vez regulada por la ECA2, que convierte AngII a Ang 1-7, cuyas acciones vaso dilatadoras y antiinflamatorias dan balance a los efectos de AngII. La ECA2 se ha relacionado con la patogenia de infecciones respiratorias como el virus respiratorio sincicial y el síndrome respiratorio agudo grave por coronavirus (SARS-CoV y SARS-CoV-2). Estudios recientes han demostrado que la ECA2 corresponde al principal receptor del SARS-CoV-2, que en conjunto con otros receptores como la serin proteasa TMPRSS2, permiten la fijación, fusión y entrada del virus a la célula huésped. En animales infectados por SARS-CoV se produce una caída de la concentración tisular de ECA2 y Ang 1-7, con la consiguiente sobreexpresión de AngII, y sus efectos vasoconstrictores e inflamatorios. Experimentos con ECA2 recombinante han mostrado un efecto protector frente a la sobreexpresión del SRAA en animales infectados por SARS-CoV, efecto similar al demostrado con el uso de bloquea- dores del receptor de AngII, AT1. La evidencia sobre el rol protector de ECA2 parece respaldar las recomendaciones respecto a no suspender estos medicamentos en la infección SARS-CoV-2. En este artículo presentamos el conocimiento actual sobre el rol del SRAA en la infección por SARS-CoV, a partir de conceptos fisiopatológicos, bases moleculares, y evidencia experimental y clínica.

Abstract: The renin-angiotensin-aldosterone system (RAAS) is the main plasma volume regulator, which maintains cardiovascular and hydrosaline homeostasis. In the classical pathway, the angiotensin converting enzyme (ACE) generates Angiotensin II (AngII), which is powerfully inflammatory and vasoconstrictive. This classical pathway is also regulated by ACE2, which converts AngI to Ang 1-9, and degrades AngII to Ang 1-7, whose vasodilatory and anti-inflammatory functions balance out the effects of AngII. ACE2 has been associated with the pathogenesis of respiratory infections such as RSV and severe acute respiratory syndrome coronavirus (SARS-CoV and SARS-CoV-2). Recent studies have shown that ACE2 corresponds to the main SARS-CoV-2 receptor, which together with other receptors such as the TMPRSS2, allows the virus to attach, fuse, and enter the host cell. These studies have shown that in animals infected with coronavirus there is a drop in tissue concentration of ACE2 and Ang 1-7, leading to overexpression of AngII and its vasoconstrictive and inflammatory effects. Experiments with recombinant ACE2 have shown a protective effect against overexpression of RAAS in coronavirus-infected animals, which is similar to that demonstrated with the use of AnglI receptor blockers (AT1). Evidence on the protective role of ACE2 seems to support the recommendations re garding not discontinuing these drugs in COVID-19 infection. In this article, we present the current knowledge about the role of RAAS in coronavirus infection, based on physiopathological concepts, molecular bases, and experimental and clinical evidence.
Descritores: Pneumonia Viral/virologia
Infecções por Coronavirus/virologia
Peptidil Dipeptidase A/metabolismo
Betacoronavirus/isolamento & purificação
-Pneumonia Viral/fisiopatologia
Sistema Renina-Angiotensina/fisiologia
Infecções por Coronavirus/fisiopatologia
Antagonistas de Receptores de Angiotensina/farmacologia
Pandemias
Enzima de Conversão de Angiotensina 2
SARS-CoV-2
COVID-19
Limites: Humanos
Animais
Tipo de Publ: Revisão
Responsável: CL1.1 - Biblioteca Central


  4 / 197 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1134445
Autor: Oliveira, Glauber Lameira; Oliveira, Talita Adão Perini; Souza, Ramon Pereira; Cabral, Soraia Izabel Corrêa; Valentim-Silva, João Rafael; Gorla, José Irineu; Fernandes-Filho, José.
Título: Frecuencia del polimorfismo genético ACTN3 R577X y ECA I/D en atletas ciegos de fútbol 5 / Frequency of genetic polymorphism ACTN3 R577X and ACE I/D in blind athletes of 5-a-side football
Fonte: Int. j. morphol;38(5):1336-1340, oct. 2020. tab.
Idioma: es.
Resumo: RESUMEN: El objetivo de este estudio fue describir la frecuencia genotípica y alélica del ACTN3 R577X y ECA I/D en atletas ciegos de fútbol 5. Se incluyó una metodología descriptiva con una muestra de 63 deportistas ciegos (28,0±5,8 años), todos varones, de equipos de fútbol 5 de alto rendimiento. El polimorfismo se determinó mediante la reacción en cadena de la polimerasa en tiempo real (RT-PCR). La estadística fue descriptiva realizada a partir de las medidas de frecuencia de genotipos y alelos. La frecuencia genotípica de la ACTN3 en los deportistas presentó la siguiente distribución: el 28,6 % con genotipo RR, el 54 % con RX y el 17,4 % con XX y frecuencia alélica del 55,6 % para el alelo R y del 44,4 % para el alelo X. En cuanto a la ECA I/D, la frecuencia genotípica fue del 63,5 % para el genotipo ID, del 22,2 % para el DD y del 14,3 % para el II. La frecuencia alélica presentó prevalencia del alelo D con el 53,9 %. El estudio constató una predominancia de los genotipos y alelos representativos de las modalidades de fuerza y velocidad para ACTN3 R577X y ECA I/D de atletas de fútbol 5.

SUMMARY: The aim of this study was to describe the genotypic and allele frequency of ACTN3 R577X and ACE I/D in blind athletes of 5-a-side football performance. A descriptive methodology was included with a sample of 63 blind male athletes (28.0 ±5.8 years) of football teams with a 5-a-side performance rating. The polymorphism was determined by means by of real-time Polymerase Chain Reaction (rt-PCR). Statistics were descriptive based on the measures of frequency of genotypes and alleles. The genotypic frequency of ACTN3 by the athletes presented the following distribution: 28.6 % with RR genotype, 54 % with RX and 17.4 % XX and allele frequency of 55.6 % for the R allele and 44.4 % for the X allele. As for ACE I/D, the genotype frequency was 63.5 % for genotype ID, 22.2 % for DD and 14.3 % for II. The allele frequency showed a predominance of the D allele with 53.9 %. The study found for ACTN3 R577X and ACE I/ D of blind athletes of 5-a-side football, a predominance of genotypes and alleles representative of strength and speed modalities.
Descritores: Futebol
Transtornos da Visão/genética
Paratletas
-Polimorfismo Genético
Actinina/genética
Cegueira/genética
Reação em Cadeia da Polimerase
Peptidil Dipeptidase A/genética
Frequência do Gene
Genótipo
Limites: Humanos
Masculino
Adulto
Responsável: CL1.1 - Biblioteca Central


  5 / 197 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-952795
Autor: Moraes, Oscar Albuquerque de; Flues, Karin; Scapini, Kátia Bilhar; Mostarda, Cristiano; Evangelista, Fabiana de Sant'Anna; Rodrigues, Bruno; Dartora, Daniela Ravizzoni; Fiorino, Patricia; Angelis, Kátia De; Irigoyen, Maria Cláudia.
Título: ACE gene dosage determines additional autonomic dysfunction and increases renal angiotensin II levels in diabetic mice
Fonte: Clinics;73:e246, 2018. tab, graf.
Idioma: en.
Resumo: OBJECTIVES: The present study aimed to investigate cardiovascular autonomic modulation and angiotensin II (Ang II) activity in diabetic mice that were genetically engineered to harbor two or three copies of the angiotensin-converting enzyme gene. METHODS: Diabetic and non-diabetic mice harboring 2 or 3 copies of the angiotensin-converting enzyme gene were used in the present study. Animals were divided into 4 groups: diabetic groups with two and three copies of the angiotensin-converting enzyme gene (2CD and 3CD) and the respective age-matched non-diabetic groups (2C and 3C). Hemodynamic, cardiovascular, and autonomic parameters as well as renal Ang II expression were evaluated. RESULTS: Heart rate was lower in diabetic animals than in non-diabetic animals. Autonomic modulation analysis indicated that the 3CD group showed increased sympathetic modulation and decreased vagal modulation of heart rate variability, eliciting increased cardiac sympathovagal balance, compared with all the other groups. Concurrent diabetes and either angiotensin-converting enzyme polymorphism resulted in a significant increase in Ang II expression in the renal cortex. CONCLUSION: Data indicates that a small increase in angiotensin-converting enzyme activity in diabetic animals leads to greater impairment of autonomic function, as demonstrated by increased sympathetic modulation and reduced cardiac vagal modulation along with increased renal expression of Ang II.
Descritores: Sistema Nervoso Autônomo/fisiopatologia
Angiotensina II/análise
Sistema Cardiovascular/fisiopatologia
Peptidil Dipeptidase A/genética
Dosagem de Genes/fisiologia
Diabetes Mellitus Experimental/fisiopatologia
Rim/enzimologia
-Nervo Vago/fisiopatologia
Glicemia/análise
Angiotensina II/metabolismo
Imuno-Histoquímica
Distribuição Aleatória
Reação em Cadeia da Polimerase
Frequência Cardíaca/fisiologia
Limites: Animais
Masculino
Camundongos
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  6 / 197 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Barbuto, José Alexandre M
Texto completo
Id: biblio-1133347
Autor: Palmeira, Patricia; Barbuto, José Alexandre M; Silva, Clovis Artur A; Carneiro-Sampaio, Magda.
Título: Why is SARS-CoV-2 infection milder among children?
Fonte: Clinics;75:e1947, 2020.
Idioma: en.
Descritores: Pneumonia Viral/metabolismo
Infecções por Coronavirus/metabolismo
Peptidil Dipeptidase A/metabolismo
Betacoronavirus/patogenicidade
-Pneumonia Viral/fisiopatologia
Pneumonia Viral/imunologia
Índice de Gravidade de Doença
Infecções por Coronavirus/fisiopatologia
Infecções por Coronavirus/imunologia
Doenças Assintomáticas
Pandemias
Enzima de Conversão de Angiotensina 2
SARS-CoV-2
COVID-19
Imunidade Inata
Limites: Humanos
Criança
Tipo de Publ: Editorial
Responsável: BR1.1 - BIREME


  7 / 197 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1133358
Autor: Peron, Jean Pierre Schatzmann; Nakaya, Helder.
Título: Susceptibility of the elderly to SARS-COV-2 infection: ace-2 overexpression, shedding, and antibody-dependent enhancement (ADE)
Fonte: Clinics;75:e1912, 2020. graf.
Idioma: en.
Projeto: FAPESP; . CNPq; . FAPESP; . CNPq.
Resumo: The world is currently facing a serious SARS-CoV-2 infection pandemic. </mac_aq>This virus is a new isolate of coronavirus, and the current infection crisis has surpassed the SARS and MERS epidemics</mac_aq> that occurred in 2002 and 2013, respectively. SARS-CoV-2 has currently infected more than 142,000 people, causing </mac_aq>5,000 deaths and spreading across more than 130 </mac_aq>countries worldwide. The spreading capacity of the virus clearly demonstrates the potential threat </mac_aq>of respiratory viruses to human health, thereby reiterating to the governments around the world that preventive </mac_aq>health policies and scientific research are pivotal to overcoming the crisis. Coronavirus disease (COVID-19) causes flu-like symptoms in most cases. However, approximately 15% of the patients need hospitalization, and 5% require assisted ventilation, depending on the cohorts studied. What is intriguing, however, is the higher susceptibility of the elderly, especially individuals who are older than 60 years of age, and have comorbidities, including hypertension, diabetes, and heart disease. In fact, the death rate in this group may be up to 10-12%. Interestingly, children are somehow less susceptible and are not considered as a risk group. Therefore, in this review, we discuss some possible molecular and cellular mechanisms by virtue of which the elderly subjects may be more susceptible to severe COVID-19. Toward this, we raise two main </mac_aq>points, i) increased ACE-2 expression in pulmonary and heart tissues in users of chronic angiotensin 1 </mac_aq>receptor (AT1R) blockers; and ii) antibody-dependent enhancement (ADE) after previous exposure to other circulating coronaviruses. We believe that these points are pivotal for a better understanding of the pathogenesis of severe COVID-19, and must be carefully addressed by physicians and scientists in the field.
Descritores: Pneumonia Viral/enzimologia
Infecções por Coronavirus/enzimologia
Peptidil Dipeptidase A/metabolismo
Anticorpos Facilitadores
Betacoronavirus
Formação de Anticorpos/imunologia
-Pneumonia Viral/imunologia
Pneumonia Viral/metabolismo
Biomarcadores/metabolismo
Regulação para Cima
Infecções por Coronavirus/imunologia
Infecções por Coronavirus/metabolismo
Peptidil Dipeptidase A/imunologia
Pandemias
Enzima de Conversão de Angiotensina 2
SARS-CoV-2
COVID-19
Limites: Humanos
Idoso
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME


  8 / 197 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1251587
Autor: Caicedo Mesa, Alberto; Méndez Fandiño, Yardany Rafael; Larrotta Salamanca, Lady Ximena; Díaz Lache, Laura Lorena; Forero Alvarado, María José; Cortés Motta, Héctor Fabio; Acosta Costilla, Álvaro Fernando.
Título: Pandemia de COVID-19 y enfermedad renal: ¿Qué sabemos actualmente? / COVID-19pandemic and kidney disease: ¿What do we currently know?
Fonte: Rev. colomb. nefrol. (En línea);7(supl.2):221-248, jul.-dic. 2020. tab, graf.
Idioma: es.
Resumo: Resumen Introducción: La enfermedad renal aguda es una patología relativamente frecuente en pacientes con infección por COVID-19, en especial en el grupo de pacientes que se encuentran críticamente enfermos; los pacientes con enfermedad renal crónica se consideran un grupo de riesgo durante la pandemia debido a la inmunosupresión asociada por lo cual es importante la detección de infección por SARS CoV-2 en estos pacientes además de quienes están en diálisis y pacientes con trasplante renal. Es de suma importancia la identificación de enfermedad renal al ingreso de pacientes con COVID-19 pues se ha demostrado que representa un indicador para valorar supervivencia y pronóstico; varios estudios han establecido que la falla renal aguda se relaciona directamente con peor pronóstico y mortalidad. Debido al impacto positivo en la supervivencia que significa el manejo oportuno de la falla renal en pacientes positivos para COVID-19. Objetivo: Presentar la información científica actual sobre la fisiopatología de falla renal en contexto de COVID-19, diagnóstico, tratamiento, estrategias de seguimiento de la función renal durante la hospitalización, manejo de unidades de diálisis, indicación de líquidos intravenosos y manejo de shock en pacientes con enfermedad renal. Métodos: Se realizó una revisión de la literatura utilizando las bases de datos PubMed, Google Scholar y Embase; los criterios de selección incluían artículos que registraran el abordaje general y específico de complicaciones en el contexto de enfermedad renal, no se usaron filtros en la búsqueda. Conclusión: La falla renal en el contexto de la infección por COVID-19 representa un aspecto importante a estudiar dentro del desarrollo de la enfermedad y requiere consideraciones especiales para su manejo.

Abstract Introduction: Acute kidney disease is relatively frequent in COVID-19 patients, especially in critically ill patients; chronic kidney disease patients are consider as a risk group during COVID-19 pandemic because of immunosuppression associated with their condition, that's why it is important to detect SARS CoV-2 in this group of patients as in dialysis patients and kidney transplant patients. It is important to identify kidney disease at admission of COVID-19 patients because it has been shown that AKI or kidney disease represent an indicator to value survival and prognosis; literature have established that acute kidney injury is related with worst prognosis and mortality. Because of positive impact in survival that means timely and early treatment and follow up of kidney disease in COVID-19 patients. Objective: To presents actual scientific information about acute kidney injury physiopathology in COVID-19 patients, diagnosis, treatment, follow up strategies during hospitalization, management of dialysis units, intravenous liquids indications and shock management in patients with kidney disease. Methods: A literature review was performed using PubMed, Google Scholar and Embase databases; the selection criteria include articles that record the general and specific approach to complications in the context of kidney disease, no filters are used in the search. Conclusion: Renal failure in the context of COVID-19 infection represents an important aspect to study during development of COVID-19 infection and requires special considerations for its correct management.
Descritores: COVID-19
Nefropatias
-Pacientes
Diálise Renal
Colômbia
Peptidil Dipeptidase A
Injúria Renal Aguda
Hospitalização
Limites: Humanos
Masculino
Feminino
Tipo de Publ: Revisão
Responsável: CO661.9


  9 / 197 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1251591
Autor: Sáenz, Jorge Armando Pulido; Trujillo, Javier; Díaz, Laura; Barba, Nelson.
Título: Receptor de la enzima convertidora de angiotensina y su correlación con COVID-19 ¿Qué conocemos hasta el momento? / Angiotensin Converting Enzime Receptor and COVID-19 Correlation ¿What do we know so far?
Fonte: Rev. colomb. nefrol. (En línea);7(supl.2):280-284, jul.-dic. 2020. graf.
Idioma: es.
Resumo: Resumen Introducción: el SARS-COV-2 es un nuevo virus que ha traído nuevos retos a los sistemas de salud a nivel mundial y que ha generado controversia en la continuidad en el uso de bloqueadores del receptor de angiotensina por su correlación fisiopatológica con el SARS-COV-2. Objetivo: presentar la evidencia disponible y las actuales recomendaciones sobre el uso de receptores de la enzima convertidora de angiotensina en el tratamiento para COVID-19. Materiales y métodos: se realizó una búsqueda narrativa en la base de datos PubMed sobre artículos que hablaran acerca del receptor de la enzima convertidora de angiotensina asociado a la pandemia actual por COVID-19. El límite de publicación fue el 13 de abril de 2020 y se incluyeron artículos en todos los idiomas. Resultados: se encontraron 14 artículos con contenido científico significativo para el objetivo de la presente revisión. Conclusión: la fisiopatología del SARS-COV-2 aún es desconocida, así como la efectividad de diferentes fármacos de uso cotidiano para su tratamiento. Dentro de los diferentes medicamentos que se han probado para detener el contagio y sus efectos están aquellos con efecto sobre el receptor de la enzima convertidora de angiotensina.

Abstract Introduction: As a new disease, SARS-COV-2 is a new challenge for healthcare system worldwide, with physiopathology under study and controversy about Angiotensin Converting Enzyme Blockers use because of It's physiopatological correlation with SARS-Cov-2. Objetive: Search for novel literature and recent recomendations about use of Angiotensin Converting Enzyme Blockers during Covid-19 illness. Materials and Methods: We look for narrative literature at PubMed Database for articles about Angiotensin Converting Enzyme and Covid-19 pandemic. Searching limit was April 13 of2.020, we included all languages. Results. We included 14 articles with significative scientific content for review objetive. Conclusion: SARS-Cov-2 Physiopatology is still unclear, also, pharmacology effectiveness in it's treatment. One of these pharmacology groups are the Angiotensin Converting Enzyme Blockers with uncertainty about it's safety during COVID-19 illness.
Descritores: Peptidil Dipeptidase A
COVID-19
-Síndrome do Desconforto Respiratório do Recém-Nascido
Receptores de Angiotensina
Colômbia
Vírus da SARS
Limites: Humanos
Masculino
Feminino
Tipo de Publ: Revisão
Responsável: CO661.9


  10 / 197 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Mady, Charles
Texto completo
Id: biblio-1136799
Autor: Alves, Silvia Marinho Martins; Alvarado-Arnês, Lúcia Elena; Cavalcanti, Maria da Glória Aureliano de Melo; Carrazzone, Cristina de Fátima Velloso; Pacheco, Antônio Guilherme Fonseca; Sarteschi, Camila; Moraes, Milton Ozorio; Oliveira Junior, Wilson Alves de; Medeiros, Carolina de Araújo; Pessoa, Fernanda Gallinaro; Mady, Charles; Lannes-Vieira, Joseli; Ramires, Felix José Alvarez.
Título: Influence of Angiotensin-converting Enzyme Insertion/Deletion Gene Polymorphism in Progression of Chagas Heart Disease
Fonte: Rev. Soc. Bras. Med. Trop;53:e20190488, 2020. tab.
Idioma: en.
Projeto: CAPES; . FAPERJ; . CNPq.
Resumo: Abstract INTRODUCTION: Chagas disease (CD) is a neglected disease caused by the parasite Trypanosoma cruzi. One-third of infected patients will develop the cardiac form, which may progress to heart failure (HF). However, the factors that determine disease progression remain unclear. Increased angiotensin II activity is a key player in the pathophysiology of HF. A functional polymorphism of the angiotensin-converting enzyme (ACE) gene is associated with plasma enzyme activity. In CD, ACE inhibitors have beneficial effects supporting the use of this treatment in chagasic cardiomyopathy. METHODS: We evaluated the association of ACE I/D polymorphism with HF, performing a case-control study encompassing 343 patients with positive serology for CD staged as non-cardiomyopathy (stage A; 100), mild (stage B1; 144), and severe (stage C; 99) forms of Chagas heart disease. For ACE I/D genotyping by PCR, groups were compared using unconditional logistic regression analysis and adjusted for nongenetic covariates: age, sex, and trypanocidal treatment. RESULTS: A marginal, but not significant (p=0.06) higher prevalence of ACE I/D polymorphism was observed in patients in stage C compared with patients in stage A. Patients in stage C (CD with HF), were compared with patients in stages A and B1 combined into one group (CD without HF); DD genotype/D carriers were prevalent in the HF patients (OR = 2; CI = 1.013.96; p = 0.04). CONCLUSIONS: Our results of this cohort study, comprising a population from the Northeast region of Brazil, suggest that ACE I/D polymorphism is more prevalent in the cardiac form of Chagas disease with HF.
Descritores: Polimorfismo Genético/genética
Doença de Chagas/genética
Peptidil Dipeptidase A/genética
Insuficiência Cardíaca/fisiopatologia
-Brasil
Inibidores da Enzima Conversora de Angiotensina
Estudos de Casos e Controles
Estudos de Coortes
Doença de Chagas/fisiopatologia
Progressão da Doença
Genótipo
Insuficiência Cardíaca/genética
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Feminino
Adulto
Responsável: BR1.1 - BIREME



página 1 de 20 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde